News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

News from ASH 2020:

1. No benefit from tranexamic acid prophylaxis in blood cancers: https://bit.ly/2K3Mah1
2. ‘Practice changing’: Ruxolitinib as second-line in chronic GVHD: https://bit.ly/3gT4kyg
3. Durable responses with anti-BCMA CAR T-cell for multiple myeloma: https://bit.ly/381f1ut
4. Five-minute SC injection of daratumumab in RRMM: https://bit.ly/3gKuZgx

Email Blood & Cancer at podcasts@mdedge.com